Vicriviroc maleate is a potent, selective, orally bioavailable CCR5 antagonist with the ability to cross the blood-brain barrier, used for inhibiting HIV-1 entry and replication in peripheral blood mononuclear cells (PBMCs); it demonstrates antiviral activity against a broad panel of HIV-1 isolates, including clinical strains such as JrFL, ADA-M, 301657, JV1083, and RU570; it also suppresses CCR5-mediated chemotactic responses to MIP-1α and inhibits RANTES-induced signaling, indicating its potential application in the treatment of CCR5-tropic HIV-1 infection.